1. Home
  2. LUNG

LUNG

Pulmonx Corporation

Logo Pulmonx Corporation

Health Care

Industrial Specialties

Nasdaq

as 04-23-2024 2:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Founded: N/A Country:
United States
United States
Employees: 279 City: REDWOOD CITY
Market Cap: 287.2M IPO Year: 2020
Target Price: $15.57 AVG Volume (30 days): 573.9K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.60 EPS Growth: N/A
52 Week Low/High: $7.72 - $14.84 Next Earning Date: 05-01-2024
Revenue: $68,675,000 Revenue Growth: 27.98%
Revenue Growth (this year): 22.07% Revenue Growth (next year): 18.57%

Share on Social Networks:

Stock Insider Trading Activity of Pulmonx Corporation (LUNG)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Rose Geoffrey Beran LUNG CHIEF COMMERCIAL OFFICER Mar 22 '24 Sell $9.36 1,184 $11,082.24 307,868 SEC Form 4
French Glendon E. III LUNG PRESIDENT AND CEO Feb 15 '24 Sell $14.60 20,000 $292,000.00 1,121,344 SEC Form 4
Rose Geoffrey Beran LUNG CHIEF COMMERCIAL OFFICER Jan 22 '24 Sell $13.13 1,184 $15,545.92 244,233 SEC Form 4
Rose Geoffrey Beran LUNG Chief Commercial Officer Dec 22 '23 Sell $12.75 1,184 $15,096.00 245,417 SEC Form 4
French Glendon E. III LUNG President and CEO Dec 21 '23 Sell $12.42 10,000 $124,200.00 1,151,344 SEC Form 4
Lehman David Aaron LUNG General Counsel Dec 1 '23 Sell $10.33 402 $4,152.66 153,246 SEC Form 4
Lehman David Aaron LUNG General Counsel Dec 1 '23 Sell $10.34 707 $7,310.38 152,539 SEC Form 4
Lehman David Aaron LUNG General Counsel Dec 1 '23 Sell $10.34 2,700 $27,918.00 149,839 SEC Form 4
French Glendon E. III LUNG President and CEO Dec 1 '23 Sell $10.34 1,040 $10,753.60 1,166,980 SEC Form 4
French Glendon E. III LUNG President and CEO Dec 1 '23 Sell $10.34 1,591 $16,450.94 1,165,389 SEC Form 4
French Glendon E. III LUNG President and CEO Dec 1 '23 Sell $10.34 4,045 $41,825.30 1,161,344 SEC Form 4
Rose Geoffrey Beran LUNG Chief Commercial Officer Nov 22 '23 Sell $10.60 1,184 $12,550.40 249,469 SEC Form 4